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ABSTRACT
Objective: The objective of this study is to evaluate the efficacy and safety of tetrahydrocurcuminoid (THC) in the treatment of oral leukoplakia.
Methods: Patients with oral mucosal lesions with clinical features of leukoplakia were selected, and an incisional biopsy of the lesion was performed 
to confirm the diagnosis. Demographic data, habit history, and complete medical history were documented. Subjects were given 2% THC gel (Sami 
Labs, Bengaluru) with advice to apply the gel to the affected areas, 5 times daily for 12 weeks. The lesion was examined, and its characteristics were 
documented in a standard manner at baseline, 3, 6, 9, and 12 weeks.
Results: Of the eight patients, 6 were males with age range from 40 to 70 years (mean age of 56 years). All the patients reported a reduction of burning 
sensation within 3 weeks of starting treatment and were completely asymptomatic by the end of the study. There was a decrease in the size of the 
lesion during the follow-up period. Reduction in thickness of the lesion was found in six of eight patients. Histological improvement a stage better was 
seen in three patients after completion of treatment. However, there was no histological improvement in four patients, and one patient progressed to 
mild dysplasia from hyperkeratosis without dysplasia.
Conclusion: THD when topically applied in gel form is remarkably effective in alleviating clinical symptoms. The remarkable histological improvement 
was seen in 3 of 8 patients.
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INTRODUCTION
Oral cancer is one of the ten most common cancers in the world and 
shows a marked geographic variation in occurrence [1]. Squamous cell 
carcinoma (SCC) is the most common type of oral cancer constituting 
about 90% of oral malignancies, in India, accounting for about 3–4% 
of all cancers. OSCCs are preceded in the majority of cases by clinically 
visible potentially malignant oral mucosal lesions which may undergo 
subsequent pathological changes from hyperplasia through dysplasia 
to the invasive neoplasm. Potentially malignant lesions of the oral cavity 
include leukoplakia, proliferative verrucous leukoplakia, erythroplakia, 
and palatal changes in reverse smokers [2].
Oral leukoplakia has recently been redefined as “predominantly 
white lesion of the oral mucosa that cannot be characterized as any 
other definable lesion; some oral leukoplakias will transform into 
cancer.” The term is strictly a clinical one and does not imply specific 
histopathological tissue alteration [3].
Various chemopreventive agents such as Vitamins A, E, and C, folates, 
and selenium have been tried in the treatment of oral leukoplakia. 
Traditional herbal agents are seen as potential chemopreventive agents 
owing to their medicinal properties. One such example is the Curcuma 
longa used in treatment due to its various pharmacological properties.
C. longa is a herb which is cultivated predominantly in tropical and 
subtropical regions of Southeast Asia. Turmeric is a household 
spice which is used in food preparations, and it also has medicinal 
properties [4]. In traditional Hindu literature, it was widely used in 
the treatment of sprains and swelling caused by injury, deworming 
agent, gallstones, and arthritis [5,6]. The major metabolite of C. longa 
is curcumin (diferuloylmethane) [7]. The mechanism of action of the 
role of curcumin as a chemopreventive agent is mainly through its 
antioxidant activity by increasing the levels of Vitamins C and E and 
preventing lipid peroxidation and DNA damage [8-10]. Cheng et al. 
evaluated the safety and efficacy of curcumin in 25 patients with various 
cases of potentially malignant disorders. The significant histological 
improvement was seen in seven cases of oral leukoplakia [11].
Holder et al. [12] discussed the metabolic products of curcumin 
and reported that one of the major by-products formed during the 
absorption in the intestine is tetrahydrocurcuminoid (THC) which 
is less polar than curcumin. Krishnakumar et al. [13] showed that 
THC showed a greater inhibitory effect than curcumin. With this 
background, an open-label, single arm, single-centered clinical trial 
was conducted to assess the efficacy and safety of THC in the treatment 
of oral leukoplakia.
METHODS
The present study was conducted in the Department of Oral Medicine 
and Radiology, Manipal College of Dental Sciences, Manipal, in 
collaboration with the Department of Ayurveda, Kasturba Hospital, 
Manipal. Approval to carry out the clinical trial was obtained from the 
Kasturba Hospital Ethical Committee (KHEC/102/2006). Subjects with 
clinical and histopathologic features consistent with oral leukoplakia 
and informed consent were included in the study. Subjects with presence 
of any concurrent infection, medical comorbidities, contraindication to 
biopsy, concurrent radiotherapy, and any medications within the past 
3 months were excluded from the study.
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Patients with oral mucosal lesions consistent with clinical diagnosis of 
leukoplakia [14] were selected for the study, and an incisional biopsy 
of the lesion was performed to confirm the diagnosis. Demographic 
data, habit history, and complete medical history were documented 
in a pro forma specially designed for the study. The characteristics of 
the leukoplakic lesion including the site/location, size, extent, surface 
texture, and symptoms were noted in the pro forma after a thorough 
clinical examination. Subjects were given 2% THC gel (Sami Labs, 
Bengaluru) with advice to apply on the affected sites in the oral cavity 
and keep it in the mouth for 30 min, 5 times daily for 12 weeks. They 
were instructed not to eat, drink, or gargle for 1 h after applying the 
medication and returned for a follow-up once in 3 weeks or earlier in 
the event of any adverse reaction associated with the application of 
the medicament. The adverse effect even with a single application was 
considered for the evaluation of drug safety. The lesion was examined, 
and its characteristics were documented in a standard manner. At the 
end of 12 weeks, clinical features of the lesion were documented, and 
repeat biopsy was performed from the same site for histopathologic 
evaluation.
All the analysis was performed using SPSS version 14. A p<0.05 was 
considered statistically significant. Comparison of the mean size of the 
lesion was made using Wilcoxon signed-rank test.
RESULTS
A total of 16 patients who met the criteria were identified for recruitment 
in the study, and only ten patients consented to the study. One patient 
developed an adverse reaction in the course of the treatment and could 
not continue the therapy, while another patient could not complete 
post-treatment assessments. Out of the eight patients, 6 were males 
with age range from 40 to 70 years (mean age of 56.37 years). All the 
eight patients enrolled in the study consumed tobacco or tobacco-
related products, presented with burning sensation as their chief 
complaint at the start of the survey. Five of the eight patients had 
leukoplakia on the buccal mucosa, two patients on the lateral border 
of the tongue, and one patient had an extensive lesion involving buccal 
mucosa, alveolar ridge, and palate. The size of the leukoplakia ranged 
from as small as 1 cm × 1 cm to as extensive as 7 cm × 5 cm. Five of eight 
patients had presented with homogenous white surface areas, and 
three patients had a speckled surface appearance that is mixed red and 
white areas. Pre-treatment histopathological diagnosis revealed three 
patients to have hyperkeratosis without dysplasia, three others to have 
mild dysplasia, and one each had moderate dysplasia and carcinoma 
in situ, respectively.
All the patients reported a reduction of burning sensation within three 
weeks of starting treatment and were completely asymptomatic by 
the end of the study. Change in surface characteristics varied among 
patients with a reduction in thickness of the lesion being the most 
consistent finding in six of eight patients, while no change in surface 
characteristics was observed in two patients.
Comparison of the size of the lesion in pre- and post-treatment phases 
was statistically significant as shown in Table 1.
Three of the eight patients histologically improved a stage better after 
completion of therapy. Of these three patients, one patient who was 
diagnosed to have carcinoma in situ was downstaged to mild dysplasia. 
Two patients were downstaged to hyperkeratosis from mild dysplasia. 
However, there was no histological improvement in four patients, and 
one patient progressed to mild dysplasia from hyperkeratosis without 
dysplasia as shown in Table 2.
DISCUSSION
Oral leukoplakia is the most common premalignant, potentially 
malignant, or precancerous lesion of the oral mucosa with a malignant 
transformation rate from various studies and locations ranging from 
0.6% to 18% [15]. Hence, prevention at the premalignant stage is 
prudent. Curcumin safely exerts chemopreventive effects against 
multiple human cancer which is mainly attributed to its potent 
anti-inflammatory agent. Curcumin is considered as a potential 
chemopreventive agent as it is known to suppress transformation, 
proliferation, and metastasis of tumors [16,17].
One of the major metabolites of curcumin which is formed during 
intestinal absorption is THC [12]. It may be involved in the physiological 
and pharmacological properties of curcumin. Krishnakumar et al. [13] 
demonstrated that THC showed a greater inhibitory effect on lipid 
peroxidation than curcumin. They concluded that THC might be 
the major metabolite which is involved in the physiological and 
pharmacological properties of curcumin. In our study, all the patients 
treated for burning sensation reported a reduction in the sensation and 
felt better symptomatically within three weeks of initiation of treatment. 
This shows that curcuminoids in gel form produced a reasonably early 
improvement with substantial improvement in the quality of life. All the 
patients were completely free from burning sensation after 12 weeks 
of treatment. Kuttan et al. reported similar reports in precancerous 
lesion [18] and Hastak et al. in oral submucous fibrosis [19].
Post-treatment histopathologic reports of biopsies showed that one 
patient who was diagnosed as carcinoma in situ before treatment was 
downstaged to mild dysplasia after treatment. Of the three patients 
diagnosed with mild dysplasia before treatment, one was downstaged 
to the absence of dysplasia. However, the other two patients remained 
at the same stage of mild dysplasia and did not show histologic 
improvement. Of the two patients who were graded before treatment 
as hyperkeratosis without dysplasia, one remained at the same stage, 
and the other progressed to mild dysplasia. One patient diagnosed 
with moderate dysplasia before treatment remained at the same 
stage and did not show histologic improvement. In a similar study of 
3 months’ duration, Cheng et al. [11] evaluated curcumin in patients 
with oral leukoplakia and found histological improvement in two of 
seven patients and one patient progressed to malignancy. One of the ten 
patients developed an adverse reaction in the course of the treatment 
and could not continue the therapy. This patient at the end of nine 
weeks reported with edema of the lips and face. The patient reported 
that the onset of swelling of the lips and face on the application of 
topical medicament was immediately withdrawn from the study group 
and recalled for a regular follow-up. Although this patient tolerated the 
drug well during the first two visits, the adverse reaction reported in 
his third visit could be attributed to a delayed hypersensitivity response 
to the drug. Kuttan et al. reported a negative reaction after application 
of curcumin in the form of ethanol extract as an ointment to external 
cancerous skin lesions [18].
CONCLUSION
Hence, we can conclude from our observations that THC when topically 
applied in gel form is remarkably effective in alleviating clinical 
symptoms. The remarkable histological improvement was seen in 
3 of 8 patients, although there was no histological improvement in 
4 patients and one patient with hyperkeratosis without dysplasia 
showed progression toward mild dysplasia. The small sample size was 
the major shortcoming of our study. Significant placebo-controlled 
trials will be necessary to evaluate as a potential therapeutic agent 
for oral leukoplakia. The results of our study, however, have shown 
that THC will safely provide symptomatic relief for patients with oral 
leukoplakia and may be an effective chemopreventive agent.
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